Full text is available at the source.
Abstract
GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 16% in chronic kidney disease populations.
- Thirteen randomized controlled trials involving 97,428 participants were analyzed, with 31,846 participants having confirmed chronic kidney disease (CKD).
- The use of GLP-1 receptor agonists was associated with a 21% reduction in a composite kidney endpoint.
- Kidney failure risk decreased by 28% with GLP-1 receptor agonist treatment.
- Urinary albumin-to-creatinine ratio (UACR) dropped by 26% among participants using GLP-1 receptor agonists.
- The benefits observed were consistent regardless of whether participants were also using SGLT2 inhibitors.
- Semaglutide was ranked highest for kidney composite outcomes in the network meta-analysis.
Simplified